IMV - IMV Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1400
+0.2300 (+7.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.9100
Open2.9600
Bid0.0000 x 900
Ask0.0000 x 900
Day's Range2.8200 - 3.1400
52 Week Range2.6900 - 7.0700
Volume8,155
Avg. Volume27,347
Market Cap159.325M
Beta (3Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-0.3390
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wirelast month

    IMV Inc. to Present at Two Upcoming Investor Conferences

    IMV Inc. , a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor con

  • Business Wirelast month

    New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL

    TSX:IMV), a clinical stage immuno-oncology corporation, today announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV’s lead candidate, DPX-Survivac, in combination with intermittent low dose cyclophosphamide and Merck’s checkpoint inhibitor Keytruda® (pembrolizumab). The trial is designed to evaluate the safety and efficacy of the combination immunotherapy in patients with persistent or recurrent/refractory diffuse large B-cell lymphoma (DLBCL). “We are highly encouraged by the level of activity that we are observing with the combination of DPX-Survivac and Keytruda in these patients with DLBCL,” said Frederic Ors, IMV’s Chief Executive Officer.

  • Business Wire2 months ago

    IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call and Webcast on June 12, 2019

    TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Wednesday, June 12, 2019, at 8:00 a.m. ET. This call will provide an update on its ongoing phase 2 clinical trials with Merck’s Keytruda® in diffuse large B-cell lymphoma (DLBCL). The webcast will be recorded and made available on the IMV website for 30 days following the call.

  • Business Wire2 months ago

    IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival

    TSX: IMV), a clinical stage immuno-oncology corporation, today announced that investigators shared new positive data for its DeCidE1 (DPX-Survivac with low dose Cyclophosphamide and Epacadostat) clinical trial at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting. These new data are from the ongoing Phase 1b/2 trial evaluating the safety and efficacy of IMV’s lead candidate DPX-Survivac and intermittent low-dose cyclophosphamide (CPA), with and without Incyte’s IDO1 enzyme inhibitor epacadostat, in patients with advanced recurrent ovarian cancer.

  • Business Wire2 months ago

    IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer

    TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the American Society of Clinical Oncology (ASCO) has published an abstract on the Company’s clinical study evaluating its lead candidate, DPX-Survivac, in recurrent advanced ovarian cancer. The abstract was released online on the ASCO website yesterday in advance of ASCO’s annual meeting in Chicago, Illinois, taking place May 31 – June 4, 2019.

  • Business Wire2 months ago

    IMV Inc. to Present at Upcoming Investor Conferences

    IMV Inc. , a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conf

  • Business Wire2 months ago

    IMV Announces Annual and Special Meeting of Shareholders Voting Results

    IMV Inc. , a clinical stage immunotherapy company , today announced the voting results from its Annual and Special Meeting of Shareholders held on Thursday May 9, 2019.

  • Business Wire2 months ago

    IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances

    IMV Inc. , a clinical stage immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2019.

  • Business Wire3 months ago

    IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019

    TSX: IMV), a clinical stage immuno-oncology corporation, today joins with World Ovarian Cancer Coalition and Ovarian Cancer Canada in recognizing World Ovarian Cancer Day (WOCD). This initiative aims to raise awareness of, and bring hope to, the global challenges faced by women living with a diagnosis of ovarian cancer. “Ovarian cancer remains one of the most underserved, difficult-to-treat forms of the disease,” said Frederic Ors, Chief Executive Officer at IMV Inc.

  • Business Wire3 months ago

    IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck’s Keytruda® in DLBCL

    Abstract on the study accepted at the 2019 ICML Meeting

  • Business Wire3 months ago

    IMV Inc. to Announce First Quarter 2019 Results and Host a Conference Call and Webcast on May 10, 2019

    TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Friday, May 10, 2019 at 8:00 a.m. ET to discuss the company’s first quarter 2019 financial and operational results. The webcast will be recorded and will then be available on the IMV website for 30 days following the call. IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

  • Business Wire3 months ago

    IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors

    TSX: IMV), a clinical stage immuno-oncology corporation, today announced that two of its abstracts have been accepted for presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 31 – June 4 in Chicago, IL. “Despite advances in other cancer treatment regimens, ovarian cancer remains a particularly difficult-to-treat disease, and one that represents one of the most underserved areas of the treatment landscape,” said Frederic Ors, Chief Executive Officer at IMV.

  • Business Wire3 months ago

    IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update

    TSX: IMV), a clinical stage immuno-oncology company, today issued the following statement regarding recent market activity. In recent weeks, shares of IMV Inc. have come under unwarranted market pressure and the management team believes it is prudent to provide a mid-quarter update on the health of the business and the Company’s upcoming Q2 clinical milestones. “From a financial and clinical results standpoint, IMV has recently achieved noteworthy milestones and, based on clinical results observed thus far, our long term outlook remains unchanged and very promising,” said Frederic Ors, Chief Executive Officer.

  • Business Wire4 months ago

    IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference

    IMV Inc. , a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer, Frederic Ors will be making an investor presentation at the 2019 Bloom Burton & Co Healthcare Investor Conference, which will be held from April 30 to May 1, 2019 in Toronto, Ontario.

  • Business Wire4 months ago

    New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMV’s Immunotherapy Program

    TSX: IMV), a clinical stage immuno-oncology corporation, today announced that preclinical research presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 demonstrated how the mechanism of action (MOA) of IMV’s proprietary DPX technology can enhance a broad spectrum of immune cell infiltration into tumors, which included T cells, Natural Killer (NK) cells, and macrophages. Analyses also revealed the differentiated characteristics of the immune cell responses and the potential implications for enhanced anti-tumor efficacy.

  • Business Wire4 months ago

    Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

    TSX: IMV), a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. “This initial phase 2 data confirms the earlier trends we saw in the phase 1b portion of the study,” said Frederic Ors, Chief Executive Officer. “It supports the potential of DPX-Survivac as a monotherapy and the use of our patient selection strategy.

  • Business Wire4 months ago

    IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

    DARTMOUTH, Nova Scotia-- -- Attained multiple milestones in DECIDE1/2 clinical program in advanced ovarian cancer Achieved initial positive data from phase 2 clinical trial in DLBCL with Merck Initiated a phase 2 basket trial across five indications under a collaboration with Merck Listed on Nasdaq and changed Corporation name to better reflect inherent value proposition Will host conference call tomorrow ...

  • Business Wire4 months ago

    IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology

    TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Canadian bioresearch consortium CQDM has awarded a grant to a collaboration among IMV, Centre de recherche du CHU de Québec-Université Laval, and La Fondation du CHU de Québec (FCHUQc).

  • Business Wire4 months ago

    IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019

    TSX: IMV), a clinical stage immuno-oncology company today announced that members of the Company’s research and development team will present results from a study at the American Association for Cancer Research (AACR) Annual Meeting 2019, which is being held March 29 to April 3 in Atlanta, Georgia. The new preclinical research highlights the unique features of DPX-based T cell immunotherapies. “The unique capabilities of our DPX-based platform and its potential to fuel novel treatment approaches continue to drive IMV’s robust research and development program,” said Marianne Stanford, PhD, Vice President, Research and Development of IMV.

  • Business Wire4 months ago

    IMV Inc. Announces Partial Exercise of Option To Purchase Additional Shares in Connection with Underwritten Public Offering of Common Shares

    TSX: IMV), a clinical-stage immuno-oncology corporation, is pleased to announce that the underwriters of its previously announced underwritten public offering (the “Offering”) of common shares have partially exercised their option to purchase additional common shares, resulting in the issuance of an additional 504,855 common shares of the Corporation at a price of C$5.45 per share for additional gross proceeds of approximately C$2.75 million. As a result of the exercise of this option, the Corporation has raised total gross proceeds of approximately C$29.46 million from the Offering, before deducting the underwriting commissions and Offering expenses.

  • Business Wire5 months ago

    IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and Webcast on March 22, 2019

    TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Friday, March 22, 2019 at 8:00 a.m. ET to discuss the company’s 2018 fourth quarter and fiscal year-end financial and operational results. The webcast will be recorded and will then be available on the IMV website for 30 days following the call. IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

  • Business Wire5 months ago

    IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference

    IMV Inc. , a clinical stage immuno-oncology company today announced that Pierre Labbé, IMV’s Chief Financial Officer will present at the Cowen and Company 39th Annual Health Care Conference, which will be held March 11-13, 2019 in Boston, MA.

  • Business Wire5 months ago

    IMV Inc. Closes Previously Announced Public Offering

    TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the closing of its previously-announced underwritten public offering (the “Offering”) of 4,900,000 common shares at a price to the public of C$5.45 per common share, for aggregate gross proceeds to the Corporation of approximately C$26.7 million, before deducting the underwriting commissions and estimated Offering expenses. In addition, the Corporation has granted the underwriters of the Offering a 30-day option to purchase up to an additional 735,000 common shares on the same terms and conditions.

  • GlobeNewswire5 months ago

    IMV Inc. Announces Pricing of Public Offering

    TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the pricing of its previously-announced underwritten public offering (the “Offering”) of 4,900,000 common shares at a price to the public of Cdn$5.45 per common share, for aggregate gross proceeds to the Corporation of approximately Cdn$26,705,000 million, before deducting the underwriting discounts and commissions and estimated Offering expenses. In addition, the Corporation has granted the underwriters of the Offering a 30-day option to purchase up to an additional 735,000 common shares on the same terms and conditions.